A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail

This study is a randomized, open label, controlled trial of extended-release buprenorphine (XR-B; BRIXADI ™ formulation) versus extended-release naltrexone (XR-NTX) in Maryland jails. A 7-site, open-label, equivalence design will randomly assign 240 adults with a history of opioid use disorder (OUD), stratified by gender and jail, who are nearing release to one of two treatment arms: 1) XR-B in jail o r 2) XR-NTX in jail, both followed by 6 monthly injections postrelease at a community treatment program.

Source: Journal of Substance Abuse Treatment - December 10, 2020 Category: Addiction Authors: Michael S. Gordon, Shannon Gwin Mitchell, Thomas R. Blue, Frank J. Vocci, Marc J. Fishman, Sean M. Murphy, Kathy Couvillion, Kelly Maher, Danielle Ryan, Kevin Wenzel, Martha L. Danner, Daniel K. Jarvis Source Type: research